Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billionWSJ • 01/09/26
Merck in Talks to Buy Revolution Medicines Per Financial Times ReportZacks Investment Research • 01/09/26
Merck could lose up to $630 million in revenue after CDC changes HPV vaccine recommendationMarket Watch • 01/07/26
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLCBusiness Wire • 01/07/26
Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3Business Wire • 01/07/26
Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett FavoritesBenzinga • 01/02/26
Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda PlaybookSeeking Alpha • 01/01/26
3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 GainsZacks Investment Research • 12/30/25